A drug for treating ovarian cancer, which can prolong the lives of patients, was first approved for use in Northern Ireland.
Women will be able to access niraparib, which is already available through the NHS in England, Scotland and Wales.
The drug will be available for women with recurrent ovarian cancer.
On average, 221 women are diagnosed with ovarian cancer in Northern Ireland every year.
Niraparib works as a targeted treatment and uses the specific weakness of cancer cells, preventing their recovery.
The drug has the potential to improve the quality of life of women suffering from this disease, and lengthen the time when the disease is stable and does not progress.
45-year-old Carol Barem, Larne, diagnosed with ovarian cancer in 2016 and hopes to be able to use niraparib.
& # 39; No cure & # 39;
“The only choice that women like me have had so far, especially if the cancer recurs outside the pelvic area, is chemotherapy,” she told BBC News NI.
“After each chemotherapy session, the effects are erased faster, and a shorter period of time elapses before the next session.
“It will not heal me, will not do anything like that. But if I use it, chemotherapy will be left out. ”
“What choice do I have?
Mrs. Bareham said that the help that the drug gives can give her precious time with her husband Neal, daughter Teya, 16, and her son Elliot, 14 years old.
“It is very hard for them. Do what happens and try to study well at school, ”she said.
“From the very first day, I said that I didn’t want your mom to have cancer that affects everything they do, or at school.
“I am one of these eejits, gray clouds are coming, but I will be there with a silver brush.
“The point is, what choice do I have? I can either curl up, or just accept it while I have life in me, and fight this disease. ”
The charitable target Ovarian Cancer said that the availability of the drug was a "game change."
“Women in Northern Ireland have finally reached parity with the rest of the UK.
“With niraparib, we are fighting ovarian cancer,” said Rebecca Rennison, director of a charitable organization for public relations and services.
The Department of Health statement said: "The ministry has now approved a recommendation from the National Institute of Health and Medical Assistance (NICE) regarding niraparib to ensure its commissioning at the local level, on the same basis as in England."
NICE is the national authority that provides guidance for the NHS and other health and welfare agencies.